Stock Scorecard



Stock Summary for Harmony Biosciences Holdings Inc (HRMY) - $33.35 as of 3/28/2025 8:05:52 PM EST

Total Score

19 out of 30

Safety Score

51 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for HRMY

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for HRMY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for HRMY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for HRMY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for HRMY (51 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for HRMY

HRMY Down 10.8% in Six Months: How Should You Play the Stock? 3/19/2025 4:14:00 PM
Should Value Investors Buy Harmony Biosciences ( HRMY ) Stock? 2/26/2025 2:40:00 PM
Harmony Biosciences ( HRMY ) Q4 2024 Earnings Call Transcript 2/25/2025 7:15:00 PM
Harmony Biosciences Holdings, Inc. ( HRMY ) Tops Q4 Earnings and Revenue Estimates 2/25/2025 1:50:00 PM
Harmony Biosciences ( HRMY ) Upgraded to Strong Buy: Here's Why 2/24/2025 5:00:00 PM
5 High Earnings Yield Value Stocks to Buy Amid Market Volatility 2/24/2025 1:06:00 PM
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth 2/20/2025 3:37:00 PM
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder - Harmony Biosciences ( NASDAQ:HRMY ) 2/19/2025 7:24:00 PM
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth 2/18/2025 4:29:00 PM
HRMY or ONC: Which Is the Better Value Stock Right Now? 2/17/2025 4:40:00 PM

Financial Details for HRMY

Company Overview

Ticker HRMY
Company Name Harmony Biosciences Holdings Inc
Country USA
Description Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/28/2025

Stock Price History

Last Day Price 33.35
Price 4 Years Ago 42.64
Last Day Price Updated 3/28/2025 8:05:52 PM EST
Last Day Volume 308,911
Average Daily Volume 760,703
52-Week High 41.61
52-Week Low 28.14
Last Price to 52 Week Low 18.51%

Valuation Measures

Trailing PE 13.13
Industry PE 37.01
Sector PE 40.10
5-Year Average PE 16.41
Free Cash Flow Ratio 4.09
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 3.31
Total Cash Per Share 8.15
Book Value Per Share Most Recent Quarter 11.54
Price to Book Ratio 2.89
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 2.67
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 57,346,000
Market Capitalization 1,912,489,100
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 89.90%
Annual Earnings Growth 12.91%
Reported EPS 12 Trailing Months 2.53
Reported EPS Past Year 2.74
Reported EPS Prior Year 2.42
Net Income Twelve Trailing Months 145,493,000
Net Income Past Year 145,493,000
Net Income Prior Year 128,853,000
Quarterly Revenue Growth YOY 19.50%
5-Year Revenue Growth 51.78%
Operating Margin Twelve Trailing Months 27.70%

Balance Sheet

Total Cash Most Recent Quarter 467,186,000
Total Cash Past Year 467,186,000
Total Cash Prior Year 353,460,000
Net Cash Position Most Recent Quarter 287,920,000
Net Cash Position Past Year 287,920,000
Long Term Debt Past Year 179,266,000
Long Term Debt Prior Year 193,566,000
Total Debt Most Recent Quarter 179,266,000
Equity to Debt Ratio Past Year 0.79
Equity to Debt Ratio Most Recent Quarter 0.79
Total Stockholder Equity Past Year 659,155,000
Total Stockholder Equity Prior Year 466,992,000
Total Stockholder Equity Most Recent Quarter 659,155,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 218,668,000
Free Cash Flow Per Share Twelve Trailing Months 3.81
Free Cash Flow Past Year 218,668,000
Free Cash Flow Prior Year 219,075,000

Options

Put/Call Ratio 0.43
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.42
MACD Signal -0.52
20-Day Bollinger Lower Band 30.83
20-Day Bollinger Middle Band 35.04
20-Day Bollinger Upper Band 39.24
Beta 0.82
RSI 45.37
50-Day SMA 33.93
150-Day SMA 38.00
200-Day SMA 37.96

System

Modified 3/27/2025 10:30:17 PM EST